Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002116 | 0.84 | FLT3 (0.46) | KMT2AMAPTRAB9ANPC1MAPK1 | |
| SCHEMBL7005437 | 0.83 | PDE4D (0.46) | KMT2AMAPTRAB9ANPC1MEN1 | |
| SCHEMBL4247199 | 0.81 | HSD17B10 (0.57) | MAPTRAB9APOLBGAAMAPK1 | |
| SCHEMBL7001335 | 0.79 | BCAT2 (0.52) | KMT2AMAPTTP53RAB9ANPC1 | |
| SCHEMBL7676444 | 0.79 | FLT3 (0.55) | KMT2AMAPTRAB9ANPC1RXFP1 | |
| SCHEMBL4758112 | 0.75 | MAPT (0.51) | KMT2AMAPTTP53KCNK3KCNK9 | |
| SCHEMBL4136987 | 0.75 | KMT2A (0.98) | KMT2AMAPTRAB9ANPC1GAA | |
| SCHEMBL7670272 | 0.73 | RAB9A (0.61) | RAB9ANPC1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL7002930 | 0.73 | RAB9A (0.53) | KMT2AMAPTTP53RAB9ANPC1 | |
| SCHEMBL1930005 | 0.73 | EPHB4 (0.40) | KMT2AMAPTTP53RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| CN-101500575-A | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMA (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2043654-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | KCNJ1, KCNJ2, TRPV1 | KMT2A 2787/4885MAPT 2226/4885TP53 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.